Lemon-Flex Company

Lemonex is a clinical-stage biotechnology company based in South Korea that specializes in the development of advanced drug delivery systems for RNA-based therapeutics and small molecules. The company's core technology, DegradaBALL, is a modular, porous silica-based nanoparticle platform designed to enhance the stability, delivery efficiency, and safety of various therapeutic payloads. Lemonex is currently advancing a pipeline of candidates, including its lead program LEM-S401, which is being evaluated in clinical trials for the treatment of hypertrophic scars. By leveraging its proprietary delivery platform, the company aims to overcome the traditional challenges associated with systemic and local delivery of nucleic acid medicines.